Manning Joseph J's Form 4 filing
Abbott Laboratories (ABT) · filed Mar 2, 2023
- Accession no.
- 0001415889-23-003910
- Filed
- Mar 2, 2023
- Trade date
- Feb 28-Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $134.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manning Joseph JCIK 0001695686 | Officer (EXECUTIVE VICE PRESIDENT) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Common shares without par value | FTax withholdingDisposed | −5,438 | $99.77 | −$542,549.26 | 63,662 | Direct | |
| Mar 1, 2023 | Common shares without par value | SSaleDisposed | −1,339 | $100.70 | −$134,837.3 | 62,323 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).